Anika Therapeutics (NASDAQ:ANIK) reported Q4 EPS of ($0.34), $0.10 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $39.62 million versus the consensus estimate of $37.71 million.
Anika Therapeutics (NASDAQ:ANIK) reported Q4 EPS of ($0.34), $0.10 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $39.62 million versus the consensus estimate of $37.71 million.